Mangoceuticals (MGRX) Prices $1,200,000 Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
Mangoceuticals, Inc. Announces Pricing of $1,200,000 Public Offering
December 15, 2023 10:39 AM ESTDallas, Texas, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (Nasdaq: MGRX) (MangoRx or the Company), a company focused on developing, marketing, and selling a variety of mens health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product (GROW) and erectile dysfunction (ED) drug (Mango), today priced its previously announced underwritten public offering of 4,000,000 shares of its common stock, par value $0.0001 per share, at a public offering price of $0.30 per share, for aggregate gross proceeds of $1,200,000 to the Company, prior to deducting underwriting discounts and commissions and other offering expenses... More
